Cidel Asset Management’s Charles River Laboratories CRL Stock Holding History

Cidel Asset Management’s Portfolio CRL Stock Details CRL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-1,000	Closed	-$214K	–	137
2022 Q2	$214K	Hold	1,000	–	–	0.01%	136
2022 Q1	$284K	Hold	1,000	–	–	0.01%	135
2021 Q4	$377K	Hold	1,000	–	–	0.01%	121
2021 Q3	$413K	Hold	1,000	–	–	0.02%	105
2021 Q2	$370K	Hold	1,000	–	–	0.02%	112
2021 Q1	$290K	Hold	1,000	–	–	0.01%	121
2020 Q4	$250K	Hold	1,000	–	–	0.01%	106
2020 Q3	$226K	Buy	+1,000	New	+$208K	0.01%	107

Other funds holding CRL

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Kayne Anderson Rudnick Investment Management Los Angeles, California $34B AUM 6.31% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Allspring Global Investments Charlotte, North Carolina $59.7B AUM 29.08% 1-Year Est. Return

JSP

Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return

Cidel Asset Management's CRL Position: Q3 2022 in Review

Cidel Asset Management sold out of Charles River Laboratories (CRL) in Q3 2022, closing a stake of 1,000 shares — an estimated $214K sold.

Cidel Asset Management first reported a position in CRL in Q3 2020 and held it in 8 quarters. The position peaked at $413K in Q3 2021. 583 funds tracked by Wall St. Rank hold CRL as of Q3 2022.

Cidel Asset Management reported no remaining Charles River Laboratories position as of Q3 2022 after selling out during the quarter.
Cidel Asset Management sold 1,000 Charles River Laboratories shares in Q3 2022, an estimated $214K.
Cidel Asset Management first reported a position in Charles River Laboratories in Q3 2020 and held it in 8 quarters.
Cidel Asset Management's Charles River Laboratories position peaked at $413K in Q3 2021.
583 funds tracked by Wall St. Rank held Charles River Laboratories as of Q3 2022.

Based on Cidel Asset Management's 13F filing for Q3 2022, filed 4 Nov 2022.